Skip to content
Evevident
Original paper
2007JAMACardiology

EVEREST

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

RCTAcute decompensated heart failure

On this page

Overview

Tolvaptan improved short-term dyspnea and weight but not long-term mortality or HF morbidity.

Clinical takeaway

EVEREST showed that vasopressin V2 blockade can aquarese and ease congestion acutely without improving survival or HF hospitalization—so do not use tolvaptan for hard heart-failure outcomes.

Key result

All-cause mortality was neutral (HR 0.98); CV death or HF hospitalization was also neutral (HR 1.04).

Practice impact

Tolvaptan is not disease-modifying HF therapy; reserve it for selected hyponatremia rather than outcome improvement.

Evidence

Study design

Randomized, double-blind, placebo-controlled, event-driven outcome trial.

Enrollment

4,133

Follow-up

Median 9.9 months.

Geography

North America, South America, Europe

Clinical question

Does oral tolvaptan started during hospitalization for worsening heart failure reduce long-term mortality or heart failure morbidity compared with placebo?

Population

  • Adults hospitalized with worsening heart failure and signs of volume overload.
  • Randomized within 48 hours of admission across 359 sites.
  • Receiving standard background heart-failure therapy.

Intervention

Oral tolvaptan 30 mg once daily for a minimum of 60 days, plus standard therapy.

Comparator

Matching placebo plus standard therapy.

Primary outcome

Dual primary endpoints: all-cause mortality (superiority and noninferiority) and cardiovascular death or hospitalization for heart failure (superiority).

Tolvaptan did not reduce long-term all-cause mortality compared with placebo.

Hazard ratio / 0.98 / CI 95% CI 0.87-1.11 / p=0.68

Key results

  • All-cause mortality: 25.9% with tolvaptan vs 26.3% with placebo; HR 0.98; 95% CI 0.87-1.11; P=.68 (noninferior for mortality, not superior).
  • Cardiovascular death or HF hospitalization: 42.0% vs 40.2%; HR 1.04; 95% CI 0.95-1.14; P=.55.
  • Secondary hard outcomes (CV mortality, CV death or hospitalization, worsening HF) were also not different.
  • Tolvaptan improved day-1 patient-assessed dyspnea, day-1 body weight, and day-7 edema.
  • In patients with hyponatremia, serum sodium increased significantly.

Harms

  • Increased thirst and dry mouth.
  • Frequencies of major adverse events were similar between groups.

Clinical Use

When to cite

  • When explaining why tolvaptan is not used to improve long-term HF outcomes despite short-term decongestion.
  • When teaching that aquaresis and early symptom improvement can occur without mortality or morbidity benefit.
  • When contrasting symptomatic/decongestive HF interventions with disease-modifying therapies.

Practice impact

  • Established that short-term aquaretic and decongestive effects of tolvaptan do not translate into better survival or fewer HF hospitalizations.
  • Supports limiting tolvaptan in HF to selected symptomatic or hyponatremia contexts rather than routine outcome-directed therapy.

Applicability

  • Most applicable to hospitalized patients with worsening volume-overloaded heart failure considered for vasopressin antagonism.
  • Useful when counseling that sodium correction or early weight loss with tolvaptan is not a surrogate for improved HF outcomes.

Limitations

  • Companion short-term clinical-status studies accompany the outcome analysis; cite the outcome paper for mortality and morbidity.
  • Background HF therapy predates contemporary ARNI/SGLT2-era GDMT.
  • Not a dedicated hyponatremia-outcomes trial; sodium rose in hyponatremic patients but hard outcomes remained neutral overall.

Common misinterpretations

  • Do not cite EVEREST as evidence against tolvaptan for clinically important hyponatremia or for ADPKD indications studied elsewhere.
  • Do not confuse this tolvaptan HF trial with EVEREST II, the MitraClip mitral-regurgitation trial.

Related evidence

DIG - Similar QuestionEMPHASIS-HF - Contrasting ResultDAPA-HF - Contrasting Result

Citation

Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial. JAMA. 2007;297(12):1319-1331. doi:10.1001/jama.297.12.1319

Tolvaptan initiated for acute treatment of patients hospitalized with heart failure had no effect on long-term mortality or heart failure-related morbidity.